In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMerieux goes public

Executive Summary

Prompted by investment firm Wendel Investissment's desire to sell its 34.5% stake, bioMerieux SA has gone public in a five times oversubscribed offering. It listed only Wendel's stock (29.5%--11.5mm shares including the overallotment) on the Premier Marche of Euronext Paris at a price of €30 ($36.86) apiece, near the high end of its original range of €26.90-31.25. Additionally, in a private placement capped at €22mm, BioMerieux offered its employees about 1mm shares priced at €24 apiece, a 20% discount to the IPO closing price.
Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
    • Saliva-based Testing
    • Urine-based Testing
Deal Status
  • Final
Deal Type
  • Financing
    • IPO
    • Other
    • Private Placement

Related Companies